New insights in risk stratification of differentiated thyroid cancer

Current Opinion in Oncology

Volumn 26, Issue 1, 2014, Pages 1-7

  Papaleontiou, Maria ^a   Haymart, Megan R ^b  

^a Division of Metabolism Endocrinology and Diabetes   (United States)

^b NONE   (United States)

Author keywords

differentiated thyroid cancer; risk stratification; survival

Indexed keywords

B RAF KINASE; ESTROGEN; MOLECULAR MARKER; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN PATCHED; PROTEIN RET; RAS PROTEIN; THYROGLOBULIN; THYROGLOBULIN ANTIBODY; THYROTROPIN; TRANSCRIPTION FACTOR PAX8; TUMOR MARKER;

AGE; AUTOIMMUNE THYROIDITIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CERVICAL LYMPH NODE; DIFFERENTIATED THYROID CANCER; DISEASE FREE SURVIVAL; DISEASE SPECIFIC SURVIVAL; DISTANT METASTASIS; GENE MUTATION; GENETIC MARKER; GROUPS BY AGE; HUMAN; LIFE EXPECTANCY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPH NODE RATIO; ONCOCYTOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENCE RISK; REVIEW; RISK FACTOR; SEX DIFFERENCE; THYROGLOBULIN BLOOD LEVEL; THYROID ADENOMA; THYROID CARCINOMA; THYROID FOLLICULAR CARCINOMA; THYROIDECTOMY; THYROTROPIN BLOOD LEVEL;

AGE FACTORS; HUMANS; LYMPH NODES; NEOPLASM STAGING; RISK ASSESSMENT; RISK FACTORS; SEX FACTORS; SURVIVAL ANALYSIS; THYROID NEOPLASMS; THYROTROPIN; TUMOR MARKERS, BIOLOGICAL;

EID: 84890563050     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0000000000000022     Document Type: Review

References (78)

1. Chen AY, Jemal A, Ward EM. Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005. Cancer 2009; 115:3801-3807.
2. Enewold L, Zhu K, Ron E, et al. Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980-2005. Cancer Epidemiol Biomarkers Prev 2009; 18:784-791.
3. Hayat MJ, Howlader N, Reichman ME, Edwards BK. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist 2007; 12:20-37.
4. Siegel R, Naishadham D, Jemal A. Cancer statistics 2013. CA Cancer J Clin 2013; 63:11-30.
5. Howlader N, Noone AM, Krapcho M, et al., editors. SEER Cancer Statistics Review, 1975-2010. Bethesda, MD: National Cancer Institute; 2013.; http://seer.cancer.gov/csr/1975-2010/, based on November 2012 SEER data submission, posted to the SEER website.
6. Sherman SI. Thyroid carcinoma. Lancet 2003; 361:501-511.
7. Hay ID, Bergstralh EJ, Goellner JR, et al. Predicting outcome in papillary thyroid carcinoma: Development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 1993; 114:1050-1057.
8. Hay ID, Grant CS, Taylor WF, McConahey WM. Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: A retrospective analysis of surgical outcome using a novel prognostic scoring system. Surgery 1987; 102:1088-1095.
9. Pasieka JL, Zedenius J, Auer G, et al. Addition of nuclear DNA content to the AMES risk-group classification for papillary thyroid cancer. Surgery 1992; 112:1154-1159.
10. Byar DP, Green SB, Dor P, et al. A prognostic index for thyroid carcinoma. A study of the E.O.R. T C Thyroid Cancer Cooperative Group. Eur J Cancer 1979; 15:1033-1041.
11. Sobin LH, Wittekind C. TNM classification of malignant tumours. 5th ed Berlin, Heidelberg, New York, Tokyo: Springer; 1997.
12. Sobin LH, Wittekind C. TNM classification of malignant tumours. 6th ed. New York: Wiley-Liss; 2002.
13. Sobin LH, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours. 7th ed. New York: Wiley-Blackwell; 2009.
14. Brierley JD, Panzarella T, Tsang RW, et al. A comparison of different staging systems predictability of patient outcome. Thyroid carcinoma as an example. Cancer 1997; 79:2414-2423.
15. Dean DS, Hay ID. Prognostic indicators in differentiated thyroid carcinoma. Cancer Control 2000; 7:229-239.
16. Verburg FA, Mader U, Tanase K, et al. Life expectancy is reduced in differentiated thyroid cancer patients-45 years old with extensive local tumor invasion, lateral lymph node, or distant metastases at diagnosis and normal in all other DTC patients. J Clin Endocrinol Metab 2013; 98:172-180.
17. Verburg FA, Mader U, Kruitwagen CL, et al. A comparison of prognostic classification systems for differentiated thyroid carcinoma. Clin Endocrinol (Oxf) 2010; 72:830-838.
18. Tuttle RM, Tala H, Shah J, et al. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: Using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid 2010; 20:1341-1349.
19. Pitoia F, Bueno F, Urcluoli C, et al. Outcome of patients with differentiated thyroid cancer risk stratified according to the American Thyroid Association and Latin-American Thyroid Society risk of recurrence classification systems. Thyroid 2013. (Epub ahead of print).
20. Nixon IJ, Ganly I, Patel SG, et al. The results of selective use of radioactive iodine on survival and on recurrence in the management of papillary thyroid cancer, based on Memorial Sloan-Kettering Cancer Center risk group stratification. Thyroid 2013; 23:683-694.
21. Tuttle RM, Leboeuf R. Follow up approaches in thyroid cancer: A risk adapted paradigm. Endocrinol Metab Clin N Am 2008; 37:419-435.
22. Wang J, Wang FW. Impact of age on clinical presentation, treatment, and cancer-specific survival of patients with small-cell carcinoma of the prostate. Clin Interv Aging 2013; 8:871-877.
23. Eaker S, Dickman PW, Bergkvist L, et al. Differences in management of older women influence breast cancer survival: Results from a population-based database in Sweden. PLoS Med 2006; 3:s25.
24. Cooper Ds, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19:1-48.
25. Oyer SL, Smith VA, Lentsch EJ. Reevaluating the prognostic significance of age in differentiated thyroid cancer. Otoralyngol Head Neck Surg 2012; 147:221-226.
26. Bischoff LA, Curry J, Ahmed J. Staging of papillary thyroid cancer: why age 45 Thyroid 2012; 22:A-74. This study highlights that patients aged 65 years and older with DTC have a progressively less favorable prognosis than younger ones. This may have implications in reinvestigating the cutoff of 45 years included in current staging guidelines.
27. Amphlett B, Lawson Z, Abdulrahman GO Jr, et al. Recent trends in the incidence, geographical distribution, and survival from thyroid cancer in wales. Thyroid Jun 2013; 14:1985-2010.
28. Akslen LA, Haldorsen T, Thoresen SO, Glattre E. Survival and causes of death in thyroid cancer: A population-based study of 2479 cases from Norway. Cancer Res 1991; 51:1234-1241.
29. Cunningham MP, Duda RB, Recant W, et al. Survival discriminants for differentiated thyroid cancer. Am J Surg 1990; 160:344-347.
30. Micheli A, Ciampichini R, Oberaigner W, et al. The advantage of women in cancer survival: An analysis of EUROCARE-4data. Eur J Cancer 2009; 45:1017-1027.
31. Tubiana M, Schlumberger M, Rougier P, et al. Long-term results and prognostic factors in patients with differentiated thyroid carcinoma. Cancer 1985; 55:794-804.
32. Carcangiu ML, Zampi G, Pupi A, et al. Papillary carcinoma of the thyroid. A clinicopathologic study of 241cases treated at the University of Florence, Italy. Cancer 1985; 55:805-828.
33. Elisei R, Molinaro E, Agate L, et al. Are the clinical and pathological features of differentiated thyroid carcinoma really changed over the last 35 years Study on 4187 patients from a single Italian institution to answer this question. J Clin Endocrinol Metab 2010; 95:1516-1527.
34. Jonklaas J, Nogueras-Gonzalez G, Mursell M, et al. The impact of age and gender on papillary thyroid cancer survival. J Clin Endocrinol Metab 2012; 97:E878-E888. This is one of the largest studies showing a sex advantage in survival for women with papillary thyroid cancer. The fact that women with stage I and II disease had better outcomes than men when diagnosed before the age of 55 years, may imply that there are hormonal influences on survival.
35. Weinstein M, Gorrindo T, Riley A, et al. Timing of menopause and patterns of menstrual bleeding. Am J Epidemiol 2003; 158:782-791.
36. McKinlay SM, Brambilla DJ, Posner JG. The normal menopause transition. Maturitas 1992; 14:103-115.
37. Yang L, Shen W, Sakamoto N. Population-based study evaluating and predicting the probability of death resulting from thyroid cancer and other causes among patients with thyroid cancer. J Clin Oncol 2013; 31:468-474.
38. Nilubol N, Zhang L, Kebebew E. Multivariate analysis of the relationship between male sex, disease-specific survival, and features of tumor aggressiveness in thyroid cancer of follicular cell origin. Thyroid 2013; 23:695-702.
39. Hsieh SH, Chen S-T, Hsueh C, et al. Gender-specific variation in the prognosis of papillary thyroid cancer TNM stages II to IV. Int J Endocrinol 2012; 2012:379097. This study showed that male sex was an independent risk factor for thyroid cancer recurrence and mortality. This has implications on sex as a potential prognostic marker. 40. 2003 United States life tables, 2003.www.cdc.gov/nchs/data/statab/lewk3 pdf. [Accessed 24 July 2013]
40. Mack WJ, Preston-Martin S, Bernstein L, et al. Reproductive and hormonal risk factors for thyroid cancer in Los Angeles County females. Cancer Epidemiol Biomarkers Prev 1999; 8:991-999.
41. Negri E, Dal Maso L, Ron E, et al. A pooled analysis of case-control studies of thyroid cancer. II.Menstrual and reproductive factors. Cancer Causes Control 1999; 10:143-155.
42. Sakoda LC, Horn-Ross PL. Reproductive and menstrual history and papillary thyroid cancer risk: The San Francisco Bay Area thyroid cancer study. Cancer Epidemiol Biomarkers Prev 2002; 11:51-57.
43. Rossing MA, Voigt LF, Wicklund KG, Daling Jr. Reproductive factors and risk of papillary thyroid cancer in women. Am J Epidemiol 2000; 151:765-772.
44. Rajoria S, Suriano R, Shanmugam A, et al. Metastatic phenotype is regulated by estrogen in thyroid cells. Thyroid 2010; 20:33-41.
45. Parlea L, Fahim L, Munoz D, et al. Follicular carcinoma of the thyroid with aggressive metastatic behavior in a pregnant woman: Report of a case and review of the literature. Hormones (Athens) 2006; 5:295-302.
46. Leboeuf R, Emerick LE, Martorella AJ, Tuttle RM. Impact of pregnancy on serum thyroglobulin and detection of recurrent disease shortly after delivery in thyroid cancer survivors. Thyroid 2007; 17:543-547.
47. Qubain SW, Nakano S, Baba M, et al. Distribution of lymph node micrometastasis in pN0 well differentiated thyroid carcinoma. Surgery 2002; 131:249-256.
48. Arturi F, Russo D, Giuffrida D, et al. Early diagnosis by genetic analysis of differentiated thyroid cancer metastases in small lymph nodes. J Clin Endocrinol 1997; 82:1638-1641.
49. Wada N, Suganuma N, Nakayama H, et al. Microscopic regional lymph node status in papillary thyroid carcinoma with and without lymphadenopathy and its relation to outcomes. Langenbecks Arch Surg 2007; 392:417-422.
50. Zaydfudim V, Feurer ID, Griffin MR, Phay JE. The impact of lymph node involvement on survival in patients with papillary and follicular thyroid carcinoma. Surgery 2008; 144:1070-1077. 52.
51. Schneider DF, Chen H, Sippel RS. Impact of lymph node ratio on survival in papillary thyroid cancer. Ann Surg Oncol 2013; 20:1906-1911. This study revisited using a specific lymph node ratio in a large patient sample to predict disease-specific mortality.
52. Beal SH, Chen SL, Schneider PD, Martinez SR. An evaluation of lymph node yield and lymph node ratio in well differentiated thyroid carcinoma. Am Surg 2010; 76:28-32.
53. Vas Nunes JH, Clark JR, Gao K, et al. Prognostic implications of lymph node yield and lymph node ratio in papillary thyroid carcinoma. Thyroid 2013; 23:811-816. This study validated that the lymph node ratio is an important independent prognostic factor in papillary thyroid cancer, and may be potentially used in DTC staging.
54. McLeod DS, Watters KF, Carpenter AD, et al. Thyrotropin and thyroid cancer diagnosis: A systematic review and dose-response meta-analysis. J Clin Endocrinol Metab 2012; 97:2682-2692.
55. Fiore E, Vitti P. Serum TSH and risk of papillary thyroid cancer in nodular thyroid disease. J Clin Endocrinol Metab 2012; 97:1134-1145.
56. Haymart MR, Repplinger DJ, Leverson GE, et al. Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage. J Clin Endocrinol Metab 2008; 93:809-814.
57. Pujol P, Daures JP, Nsakala N, et al. Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer. J Clin Endocrinol Metab 1996; 81:4318-4323.
58. Jonklaas J, Sarlis NJ, Litofsky D, et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid 2006; 16:1229-1242.
59. Hovens GC, Stokkel MP, Kievit J, et al. Associations of serum thyrotropin concentrations with recurrence and death in differentiated thyroid cancer. J Clin Endocrinol Metab 2007; 92:2610-2615.
60. Haymart MR, Glinberg SL, Liu J, et al. Higher serum TSH in thyroid cancer patients occurs independent of age and correlates with extrathyroidal extension. Clin Endocrinol (Oxf) 2009; 71:434-439.
61. Kim SS, Lee BJ, Lee JC, et al. Preoperative serum thyroid stimulating hormone levels in well differentiated thyroid carcinoma is a predictive factor for lateral lymph node metastasis as well as extrathyroidal extension in Korean patients: A single-center experience. Endocrine 2011; 39:259-265.
62. McLeod DSA, Cooper DS, Ladenson PW, et al. Prognosis of differentiated thyroid cancer in relation to serum TSH and thyroglobulin antibody status at time of diagnosis. Thyroid 2013. (Epub ahead of print).
63. Kim ES, Lim DJ, Baek KH, et al. Thyroglobulin antibody is associated with increased cancer risk in thyroid nodules. Thyroid 2010; 20:885-891.
64. Xing M, Haugen BR, Schlumberger M. Progress in molecular-based management of differentiated thyroid cancer. The Lancet 2013; 381:1058-1069.
65. Ricarte-Filho JC, Ryder M, Chitale DA, et al. Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res 2009; 69:4885-4893.
66. Tufano RP, Bishop J, Wu G. Reoperative central compartment dissection for patients with recurrent/persistent papillary thyroid cancer: Efficacy, safety, and the association of the BRAF mutation. Laryngoscope 2012; 122:1634-1640.
67. Barollo S, Pennelli G, Vianello F, et al. BRAF in primary and recurrent papillary thyroid cancers: The relationship with (131)I and 2-[(18)F]fluoro-2- deoxy-Dglucose uptake ability. Eur J Endocrinol 2010; 163:659-663.
68. Henderson YC, Shellenberger TD, Williams MD, et al. High rate of BRAF and RET/PTC dual mutations associated with recurrent papillary thyroid carcinoma. Clin Cancer Res 2009; 15:485-491.
69. Prescott JD, Sadow PM, Hodin RA, et al. BRAF V600E status adds incremental value to current risk classification systems in predicting papillary thyroid carcinoma recurrence. Surgery 2012; 152:984-990.
70. Xing M. Prognostic utility of BRAF mutation in papillary thyroid cancer. Mol Cell Endocrinol 2010; 32:86-93.
71. Zheng X, Wei S, Han Y, et al. Papillary microcarcinoma of the thyroid: Clinical characteristics and BRAF(V600E) mutational status of 977 cases. Ann Surg Oncol 2013; 20:2266-2273.
72. Xing M, Alzahrani AS, Carson KA, et al. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA 2013; 309:1493-1501. This is the only international multicenter study that showed the presence of BRAFV600E mutation was significantly associated with increased cancer-related mortality.
73. Zoghlami A, Roussel F, Sabourin JC, et al. BRAF mutation in papillary thyroid carcinoma: Predictive value for long-term prognosis and radioiodine sensitivity. Eur Ann Otorhinolaryngol Head Neck Dis 2013. (Epub ahead of print).
74. Rusinek D, Szpak-Ulczok S, Jarzab B. Gene expression profile of human thyroid cancer in relation to its mutational status. J Mol Endocrinol 2011; 47:R91-R103.
75. Fukahori M, Yoshida A, Hayashi H, et al. The associations between RAS mutations and clinical characteristics in follicular thyroid tumors: New insights from a single center and a large patient cohort. Thyroid 2012; 22:683-689.
76. Gupta N, Dasyan AK, Carty SE, et al. RAS mutations in thyroid FNA specimens are highly predictive of predominantly low-risk follicular pattern cancers. J Clin Endocrinol Metab 2013; 98:E914-E922.
77. Leeman-Neill RJ, Brenner AV, Little MP, et al. RET/PTC and PAX8/PPARg chromosomal rearrangements in post-Chernobyl thyroid cancer and their association with iodine-131 radiation dose and other characteristics. Cancer 2013; 119:1792-1799.
78. De Vries MM, Celestino R, Castro P, et al. RET/PTC rearrangement is prevalent in follicular Hurthle cell carcinomas. Histopathology 2012; 61:833-843.